RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
RenovoRx (Nasdaq: RNXT) announces that their research on the Trans-Arterial Micro-Perfusion (TAMP) therapy platform will be honored at the SIR 2025 Annual Scientific Meeting as a Journal of Vascular and Interventional Radiology Award-Winning Paper.
The peer-reviewed research demonstrates that TAMP significantly enhances drug delivery with a 100-fold increase in local tissue concentration compared to conventional intravenous delivery. The paper, titled 'Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model,' will be presented by Dr. Ramtin Agah at the conference in Nashville on April 1, 2025.
Unlike traditional systemic chemotherapy, TAMP's innovative approach uses RenovoCath®, an FDA-cleared drug-delivery device, to directly target solid tumors while potentially reducing systemic toxicity. The company is currently conducting the TIGeR-PaC Phase III clinical trial and accelerating the commercialization of RenovoCath as a standalone device through partnerships with leading oncology centers nationwide.
RenovoRx (Nasdaq: RNXT) annuncia che la loro ricerca sulla piattaforma terapeutica Trans-Arterial Micro-Perfusion (TAMP) sarà onorata durante il SIR 2025 Annual Scientific Meeting come un articolo premiato dalla Journal of Vascular and Interventional Radiology.
La ricerca, sottoposta a revisione paritaria, dimostra che TAMP migliora significativamente la somministrazione del farmaco con un aumento di 100 volte nella concentrazione locale del tessuto rispetto alla somministrazione endovenosa convenzionale. L'articolo, intitolato 'Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model,' sarà presentato dal Dr. Ramtin Agah alla conferenza di Nashville il 1° aprile 2025.
Contrariamente alla chemioterapia sistemica tradizionale, l'approccio innovativo di TAMP utilizza RenovoCath®, un dispositivo per la somministrazione di farmaci approvato dalla FDA, per mirare direttamente ai tumori solidi riducendo potenzialmente la tossicità sistemica. L'azienda sta attualmente conducendo lo studio clinico di fase III TIGeR-PaC e accelerando la commercializzazione di RenovoCath come dispositivo autonomo attraverso partnership con i principali centri oncologici a livello nazionale.
RenovoRx (Nasdaq: RNXT) anuncia que su investigación sobre la plataforma terapéutica Trans-Arterial Micro-Perfusion (TAMP) será reconocida en la SIR 2025 Annual Scientific Meeting como un artículo premiado por la Journal of Vascular and Interventional Radiology.
La investigación revisada por pares demuestra que TAMP mejora significativamente la entrega de medicamentos con un aumento de 100 veces en la concentración local del tejido en comparación con la entrega intravenosa convencional. El artículo, titulado 'Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model,' será presentado por el Dr. Ramtin Agah en la conferencia en Nashville el 1 de abril de 2025.
A diferencia de la quimioterapia sistémica tradicional, el enfoque innovador de TAMP utiliza RenovoCath®, un dispositivo de entrega de medicamentos aprobado por la FDA, para dirigirse directamente a los tumores sólidos mientras potencialmente reduce la toxicidad sistémica. La empresa está llevando a cabo actualmente el ensayo clínico de fase III TIGeR-PaC y acelerando la comercialización de RenovoCath como un dispositivo independiente a través de asociaciones con centros de oncología líderes en todo el país.
RenovoRx (Nasdaq: RNXT)는 Trans-Arterial Micro-Perfusion (TAMP) 치료 플랫폼에 대한 연구가 SIR 2025 Annual Scientific Meeting에서 Journal of Vascular and Interventional Radiology의 수상 논문으로 선정되었다고 발표했습니다.
동료 검토 연구는 TAMP가 기존의 정맥 주사 전달에 비해 국소 조직 농도를 100배 증가시키는 약물 전달을 상당히 향상시킨다는 것을 보여줍니다. 'Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model'라는 제목의 논문은 2025년 4월 1일 내슈빌에서 열리는 회의에서 Dr. Ramtin Agah에 의해 발표될 예정입니다.
전통적인 전신 화학요법과 달리 TAMP의 혁신적인 접근 방식은 FDA 승인을 받은 약물 전달 장치인 RenovoCath®를 사용하여 고형 종양을 직접 표적하고 전신 독성을 줄일 수 있습니다. 이 회사는 현재 TIGeR-PaC 3상 임상 시험을 진행 중이며, 전국의 주요 종양학 센터와 파트너십을 통해 RenovoCath를 독립형 장치로 상용화하는 속도를 높이고 있습니다.
RenovoRx (Nasdaq: RNXT) annonce que sa recherche sur la plateforme thérapeutique Trans-Arterial Micro-Perfusion (TAMP) sera honorée lors de la SIR 2025 Annual Scientific Meeting en tant qu'article primé par la Journal of Vascular and Interventional Radiology.
La recherche évaluée par des pairs démontre que TAMP améliore significativement l'administration des médicaments avec une augmentation de 100 fois de la concentration locale des tissus par rapport à l'administration intraveineuse conventionnelle. L'article, intitulé 'Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model,' sera présenté par le Dr. Ramtin Agah lors de la conférence à Nashville le 1er avril 2025.
Contrairement à la chimiothérapie systémique traditionnelle, l'approche innovante de TAMP utilise RenovoCath®, un dispositif de délivrance de médicaments approuvé par la FDA, pour cibler directement les tumeurs solides tout en réduisant potentiellement la toxicité systémique. L'entreprise mène actuellement l'essai clinique de phase III TIGeR-PaC et accélère la commercialisation de RenovoCath en tant que dispositif autonome grâce à des partenariats avec des centres d'oncologie de premier plan à l'échelle nationale.
RenovoRx (Nasdaq: RNXT) gibt bekannt, dass ihre Forschung zur Trans-Arterial Micro-Perfusion (TAMP) Therapieplattform auf dem SIR 2025 Annual Scientific Meeting als preisgekröntes Papier der Journal of Vascular and Interventional Radiology gewürdigt wird.
Die peer-reviewed Forschung zeigt, dass TAMP die Medikamentenabgabe signifikant verbessert, mit einem 100-fachen Anstieg der lokalen Gewebekonzentration im Vergleich zur herkömmlichen intravenösen Abgabe. Das Papier mit dem Titel 'Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model' wird von Dr. Ramtin Agah auf der Konferenz in Nashville am 1. April 2025 präsentiert.
Im Gegensatz zur herkömmlichen systemischen Chemotherapie verwendet der innovative Ansatz von TAMP RenovoCath®, ein von der FDA zugelassenes Medikamentenabgabegerät, um gezielt solide Tumore anzuvisieren und dabei potenziell die systemische Toxizität zu reduzieren. Das Unternehmen führt derzeit die TIGeR-PaC Phase-III-Studie durch und beschleunigt die Kommerzialisierung von RenovoCath als eigenständiges Gerät durch Partnerschaften mit führenden Onkologiezentren im ganzen Land.
- None.
- None.
Peer-reviewed paper will be honored as a Journal of Vascular and Interventional Radiology Award-Winning Paper
Pre-clinical data show that TAMP increases intra-arterial pressure, improving drug delivery with 100-fold increase in local tissue concentration of the therapy
TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of existing and new treatments
The peer-reviewed paper, published in the July 2024 edition of JVIR, is being honored during the conference’s JVIR Award-Winning Paper Scientific Session in
The JVIR Award-Winning Paper, titled “Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model: A Mechanism Recruiting the Vasa Vasorum for Localized Therapies,” is authored by Khashayar Farsad, MD, PhD of the Department of Interventional Radiology at Oregon Health and Science University, and co-authored by Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, together with other researchers, including RenovoRx’s founder and Chief Medical Officer, Dr. Ramtin Agah. During JVIR Award-Winning Paper Scientific Session, Dr. Agah will present the findings of the paper. The JVIR abstract can be accessed here: https://pubmed.ncbi.nlm.nih.gov/38508449/.
“We are deeply honored to be recognized for our research at SIR 2025 Annual Scientific Meeting in the JVIR Award-Winning Paper Scientific Session,” said Dr. Agah. “This recognition reflects RenovoRx’s innovation and treatment paradigm that may translate to benefits in treatment of patients with solid tumors. I look forward to presenting these findings at the upcoming conference, and my colleagues and I are grateful for this recognition and validation of our commitment to advancing the field of interventional oncology.”
Currently, most cancer patients with solid tumors receive chemotherapy intravenously, introducing the drug systemically into the entire body. This is well-known to cause adverse side effects. RenovoRx’s patented TAMP therapy platform is designed to bypass traditional systemic delivery methods and provide targeted delivery to bathe the target solid tumor in chemotherapy. This locoregional delivery also creates the potential to minimize a therapy’s systemic toxicities.
The pre-clinical data published in JVIR showed a 100-fold (two orders of magnitude) increase in local tissue concentration of the therapy with TAMP compared to conventional intravenous (IV) delivery. TAMP also showed advantages compared to historically available intra-arterial (IA) delivery approaches. TAMP’s novel approach to treatment offers the potential to increase an oncology therapy’s efficacy, improve safety, and widen its therapeutic window by focusing its distribution uniformly in target tissue.
“TAMP has the potential to provide a valuable treatment option to patients who have been diagnosed with solid tumors that may be difficult-to-treat,” said Dr. Farsad. “This platform also has the potential to extend across a variety of unmet needs for localized therapeutic drug delivery. This study shows a possible mechanism for how TAMP can increase local therapeutic tissue concentration in solid tumors that is independent from traditional catheter-directed therapy. We are awaiting final outcomes from RenovoRx’s TIGeR-PaC Phase III clinical trial, currently underway, to further validate this benefit.”
“We believe this award further supports our decision to accelerate the commercialization of our proprietary RenovoCath as a standalone device,” said Shaun Bagai, CEO of RenovoRx. “We are rapidly expanding efforts and forging stronger relationships with leading oncology centers nationwide who are using RenovoCath. This progress not only positions our company for growth but also reinforces our growing leadership in the oncology space, unlocking substantial value-creation opportunities. We continue to scale our commercialization efforts and, in tandem, progress our Phase III TIGeR-PaC trial in the most capital efficient manner.”
About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-F-Universal-IFU.pdf.
About the TIGeR-PaC Clinical Trial
TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of LAPC. RenovoRx’s first investigational drug-device combination product candidate using the TAMP therapy platform enabled with the Company’s FDA-cleared RenovoCath® device for the intra-arterial administration of chemotherapy, gemcitabine (IAG).
About RenovoRx, Inc.
RenovoRx (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel,
In addition to the RenovoCath device, RenovoRx is also evaluating our novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). IAG is being evaluated under a
The combination product candidate, which is enabled the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides 7 years of market exclusivity upon new drug application approval by the FDA.
RenovoRx is also engaged in implementing commercialization strategies utilizing its TAMP technology and FDA-cleared RenovoCath device as stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, certain of these customers have already initiated repeat orders as RenovoRx works to expand the number medical institutions that have initiated the process for RenovoCath purchase orders, including several esteemed, high volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity either on its own or in tandem with a medical device commercial partner.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release, the fireside chat referred to herein, and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our pre-clinical and clinical trials and studies, including the overall timing and timing for additional interim data readouts and full patient enrollment for our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential of RenovoCath® or TAMP™ as standalone commercial products, our anticipated timing for and levels of revenue generation from RenovoCath sales, and our commercialization plans in general, (iii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iv) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, commercial plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our execution of our commercial strategy for RenovoCath or our TAMP technology may not lead to viable or repeating revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of TIGeR-PaC and any other preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326997651/en/
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T:212-896-1254
RenovoRX@KCSA.com
Source: RenovoRx, Inc.